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The effect of PMMA-based protein-leaking dialyzers on total
plasma homocysteine levels.
Background. Hyperhomocysteinemia is a well-recognized in-
dependent risk factor for cardiovascular disease in end-stage renal
disease (ESRD) patients. Since homocysteine (Hcy) largely binds
to serum proteins (80 to 90%), in this study we investigated the
possibility that polymethylmethacrylate (PMMA)-based protein-
leaking dialyzers could reduce total plasma Hcy (tHcy) levels
in ESRD patients.
Methods. Two matched groups of patients (N 13) showing
mild to intermediate hyperhomocysteinemia on standard he-
modialysis (HD) with conventional non-protein-leaking dialyz-
ers were included. In the control group membranes were main-
tained the same, while the study group was switched to protein-
leaking dialyzers (BK-F series; Toray, Japan) and studied for
6 months. tHcy was measured by high performance liquid chro-
matography (HPLC) at baseline and after 1, 3, and 6 months.
Proteins and Hcy were also measured in the spent dialysate.
Results. The pre-HD levels of tHcy in the control group re-
mained close to baseline values (26.6  5.0 mol/L), while in
the study group at 1, 3, and 6 months they decreased from a
baseline value (in mol/L) of 25.3  5.9 to 21.5  4.5, 16.9 
4.0, and 17.2  4.2, respectively (P  0.01 for values at 3 and
6 months vs. baseline). The intra-HD drop of tHcy (HDHcy)
slightly but progressively decreased during the 3 steps on pro-
tein-leaking dialyzers and a positive correlation was found be-
tween HDHcy and pre-HD levels of tHcy. In spent dialysate
samples from protein-leaking dialyzer–treated patients, the
amount of protein-bound Hcy (bHcy) was approximately 10
times higher than in non-protein-leaking dialyzers, but the
HDHcy observed in non-protein-leaking dialyzers and protein-
leaking dialyzers was comparable. Serum proteins and albumin
were only slightly affected by protein-leaking dialyzers.
Conclusion. This study demonstrates that protein-leaking
dialyzers used with a pure diffusive technique significantly lower
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pre-HD tHcy (approximately 33% of starting levels after 3
months of treatment) in ESRD patients. A possible underlying
mechanism for this effect could be the removal of large molecu-
lar weight solutes responsible for a defective metabolism of
the Hcy, as the removal of bHcy with protein-leaking dialyzers
seems not sufficient, per se, to explain this steady reduction of
tHcy levels in pre-HD.
Homocysteine (Hcy) is a sulfur-containing amino acid
formed during methionine metabolism [1]. Its accumula-
tion is a well-recognized independent risk factor for car-
diovascular diseases such as myocardial infarction, stroke,
and thromboembolic disease in end-stage renal disease
(ESRD) patients and the general population [2–5].
Under normal conditions, total plasma Hcy (tHcy) con-
centration is a function of its formation in tissues, elimina-
tion by renal clearance, and tissue uptake and transfor-
mation [6]. Only a minor percentage [i.e., the free form
(fHcy)] is eliminated through the glomerular filter, while
the majority is removed by metabolic processing, with
the kidney playing an important role in that it eliminates
up to 70% of the tHcy pool in the body [7]. When exces-
sive amounts of Hcy are produced in tissues and/or the
catabolic routes are defective, the accumulation of Hcy
brings cells to export it in the plasma. Herein, Hcy is in
equilibrium with the fHcy and the more prevalent pro-
tein-bound form (bHcy), which can represent up to 80%
to 90% of the tHcy [8].
Hyperhomocysteinemia in ESRD patients appears to
be the consequence of a decreased clearance and impaired
metabolism of Hcy [9]. Genetic factors and an insuffi-
cient correction of the uremic toxicity can sustain hyper-
homocysteinemia in some ESRD patients and can lead
to unsuccessful therapy [10, 11]. The latter of these two
is essentially based on supplementation protocols of folic
acid, vitamin B12, and B6 [12], in that they are important
cofactors for the enzymes of the remethylation and trans-
sulfuration pathways in the Hcy metabolism [13, 14].
Hemodialysis (HD) is not considered a therapy against
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Table 1. Main characteristics of patients at baseline evaluation
Control group Study group
(N13) (N13)
Sex M7; F6 M7; F6
Age years 62.612.0 67.614.8
Dialytic age months 49.331.8 46.838.2
Membrane type B14; CA5; CR4 B15; CA4; CR4
Kt/V weekly 3.90.7 4.10.7
Urea mg/dL 149.643.4 153.449.8
Creatinine mg/dL 9.81.9 9.72.3
Residual CrCl ml/min 1 1
Hematocrit % 33.03.6 32.54.1
Cholesterol mg/dL 195.435.2 189.855.7
Triglycerides mg/dL 175.5123.2 179.1137.0
Total proteins g/dL 6.70.4 6.90.5
Albumin g/dL 4.10.3 4.00.4
Folic acid ng/mL 22.918.0 23.319.5
Vitamin B12 pg/mL 375.9160.5 379.3169.5
tHcy lmol/L 26.65.0 25.35.9
hyperhomocysteinemia. Although the intra-HD decrease
in tHcy could reach values 30% with different types
of dialyzers [15–17], the inter-HD concentrations of tHcy
remain above normal levels also after a so-called “ade-
quate HD.” This seems to be the consequence of an
insufficient removal of Hcy, as current dialysis methods
and membrane types only marginally affect the predomi-
nant form (i.e., the bHcy) and its equilibrium with the
pool of Hcy in tissues.
Protein-leaking dialyzers have been recently proposed
as a specific solution to decrease levels of protein-bound
toxins [18, 19]. In particular, polymethylmethacrylate
(PMMA)-based protein-leaking dialyzers (commercial
name BK-F) have been the former example of membranes
that, even when used in standard HD procedures, are able
to remove a significant amount of proteins in a broad range
of molecular weights [19]. Early studies showed that protein
bound toxins and other high molecular weight toxins
could be removed during dialysis with protein-leaking
dialyzers; these solutes include advanced glycoxidation
end products [abstract; Galli F et al, J Am Soc Nephrol
12:1831, 2001] [19], erythropoiesis inhibitors [20, 21], and
the same Hcy [19, 22]. The direct clearance of bHcy could
be counted as a mechanism through which protein-leak-
ing dialyzers might reduce tHcy; alternatively, protein-
leaking dialyzers might remove high molecular weight
toxins able to inhibit the Hcy metabolism, as proposed
by the basis of early studies on polysulfone (PS)-based
protein-leaking dialyzers [22] and high-flux non-protein-
leaking dialyzers [15, 16].
The present study investigated the protein leakage
through PMMA-based protein-leaking dialyzers as a
strategy to steadily decrease pre-HD levels of tHcy in
ESRD patients. Intra- and inter-HD changes of tHcy
and the amount of bHcy removed in the spent dialysate
were assessed in detail.
METHODS
Patient selection and study design
The participants included in the study (N 26; M14,
F12, mean age, 66.1  17.1 years) were patients on
standard (three times/week) bicarbonate HD (mean di-
alysis age, 47.1 40.8 months) showing mild to interme-
diate hyperhomocysteinemia (according to the current
classification [12], the normal range of plasma tHcy is
between 5 and 15mol/L; mild, intermediate, and severe
hyperhomocysteinemia are defined as concentrations of
15 to 25, 25 to 50 and 50 mol/L, respectively) and on
folate therapy for at least 6 months (from 10 to 15 mg/
wk). None of them received supplements of vitamin B6
and B12.
Exclusion criteria included acute and chronic infec-
tious disease, malnutrition (serum albumin cut-off 3.3
g/dL), malignancy, and any other known metabolic de-
fect and therapy that would affect Hcy metabolism. In
particular, the presence of major folate deficiency was
excluded on the basis of a preliminary test aimed to
establish tHcy levels during the enrollment.
The study was designed as a 9-month prospective two-
step controlled trial. At the basal step, patients were
enrolled and maintained for 3 months on treatment with
non-protein-leaking dialysers including high-flux PMMA
(B1 series; Toray, Japan), low-flux cellulose acetate (CA)
(Cobe, Japan), and cuprammonium rayon (CR) (Te-
rumo, Japan). In the second step, patients were randomly
assigned to two subgroups, the main characteristics of
which are shown in Table 1. The first subgroup that
served as control was maintained on treatment with the
same type of dialyzers used at the inclusion, while in the
second subgroup (study group), the patients were assigned
to the treatment with protein-leaking dialyzers (BK-F se-
ries; Toray, Japan) for a period of 6 months. The main
physical characteristics of this membrane series are de-
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Table 2. Physical characteristics of protein-leaking dialyzer
series membranes
Pore size A˚ 100
Porosity % 62
Nominal cut-off kDa 70
Inside diameter lm 200
Wall thickness lm 30
Effective surface area m2 1.6
UFR in vitro mL/hr at 100 mm Hg 2000
Sieving coefficient of albumin ca. 0.03
scribed in Table 2. Criteria for computerized randomiza-
tion included the presence of clinical and dialysis vari-
ables comparable in the study and control group; major
parameters scored were tHcy levels at the enrollment,
comorbidity as severe hypertension, diabetes, and hyper-
lipidemia, age and sex, plasma proteins, vitamin supple-
ments, and pharmacologic therapy. Major dialysis param-
eters scored were dialysis age and schedule (frequency
and duration), membrane surface area, blood and dialy-
sate flows, and Kt/V. All of these parameters did not
change during the study in the two groups of patients.
A group of 15 sex- and age-matched healthy controls
was also included in the study. Informed consent was
obtained from each subject.
Sample collection
Blood sampling was carried out in the midweek dial-
ysis of the last week at baseline (step 1) and after 1, 3,
and 6 months in the step 2. Five mL of blood were drawn
by vacutainer technique into heparinized green-top tubes
just before and after HD. Plasma samples were obtained
by centrifugation immediately after collection and pre-
served at 80	C until assayed.
Twenty liters of dialysis fluid (from the 10th to the 50th
minute of HD) were collected in the study group in the
last dialysis of the step 1 and at the first dialysis in the
step 2. Samples were then concentrated to 5 mL by ultra-
filtration with a 10 kD cut-off membrane (Pall Gelman
Laboratory, Vernon Hills, IL, USA) and stored at80	C.
As a preliminary evaluation, we measured the protein
concentration in the dialysate collected during HD with
non-protein-leaking dialyzer and protein-leaking dialyzer
membranes to evaluate the removal of plasma proteins.
Hematochemical analyses
The following parameters were monitored by routine
analysis of blood samples: vitamin B12, folic acid, total
proteins and albumin, lipids, creatinine, urea, and hema-
tocrit. Kt/V values were calculated using the single-pool
method.
Total homocysteine analysis
Chemicals. D,l-homocysteine, l-cysteine, and cysteinyl-
glycine were obtained from Sigma (Milan, Italy); these
compounds were used as standards and dissolved in 0.05
mol/L hydrochloric acid to make a stock solution with
a concentration of 2.5 mmol/L and stored at 4	C; the work-
ing standard solutions were made up freshly by dilution
of the stock solution with 0.01 mol/L hydrochloric acid.
Analytic grade trichloroacetic acid, ortophosphoric acid,
potassium dihydrogen phosphate, and acetonitrile were
purchased from Sigma (Milan, Italy). Tri-n-butylphosphine
was obtained from Fluka (Milan, Italy) and used as 10%
(vol/vol) solution in dimethylformammide. 7-Fluoro-2-
oxa-1,3-diazole-4-sulfonate (SBD-F) was obtained from
Sigma and used as a 1 mg/mL solution in 0.125 mol/L
borate buffer, pH 8.0, containing 4 mmol/L ethylene
diaminetetraacetic acid (EDTA).
Plasma and dialysate processing
Samples were treated accordingly with the procedure
described by Ubbink [23] with some minor changes.
Briefly, 0.1 mL aliquot of plasma or protein concentrates
from dialysate samples were treated with 10 L of 10%
(vol/vol) tri-n-butylphosphine for 30 minutes at 4	C. The
solution was then mixed with 0.1 mL of 10% (weight/vol)
trichloroacetic acid cold solution containing 1 mmol/L
Na2 EDTA under vigorous mixing, followed by centrifu-
gation at 10,000g for 5 minutes. To a 0.1 mL aliquot of
the clear supernatant were added 0.02 mL of 1.55 mol/L
sodium hydroxide solution, 0.25 mL of 0.125 mol/L po-
tassium borate buffer, pH 8.0, containing 4 mmol/L Na2
EDTA, and 0.02 mL of 1 mg/mL of SBD-F reagent; the
derivatization was carried out at 70	C for 10 minutes.
The solution was then cooled in crushed ice, centrifuged
at 2000g for 5 minutes, and an aliquot of 0.05 mL was
subjected to high performance liquid chromatography
(HPLC) analysis. This procedure allows measurement
of the tHyc in the samples (protein-bound and free Hcy).
HPLC analysis
Analyses were performed using an HPLC apparatus
equipped with a model 880 PU Jasco pump (Jasco Eu-
rope, s.r.l., Cremerla, Italy) and a Rheodyne 7125 injec-
tion valve fit with a 100 L sample loop (Rheodyne
Europe GmbH, Benshoim, Germany). The separation
of derivatized thiol compounds in plasma was performed
at room temperature on an analytical column named
Spherisorb ODS2 (150 
 4 mm I.D., 5  particle size)
and protected by an ODS2 guard cartridge (30 
 2 mm)
(Wahrs Spa, Milan, Italy).
The fluorescence of derivatized analytes was measured
at 515 nm with excitation at 385 nm, using a model FP
920 Jasco spectrofluorimeter equipped with a 12 L flow
cell. The detector signal was recorded and the peak quan-
tified with a Model 3394 Hewlett Packard integrator
(Geneva, Switzerland).
Chromatographic elution was carried out isocratically
at 1.0 mL/minute flow rate, using as the mobile phase a
mixture of 0.05 mol/L potassium dihydrogen phosphate
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Table 3. Pre- and post-HD levels and intra-HD decrease (HDHcy) of tHcy in patients treated with non-protein-leaking dialyzers and
protein-leaking dialyzers (BK-F)
Patients on non-protein-leaking dialyzers
(control group)
Patients on protein-leaking dialyzers (study group)
Mean % decrease vs.
Plasma tHcy lmol/L Plasma tHcy lmol/L baseline levels
Pre-HD Post-HD Absolute HDHcy Pre-HD Post-HD Pre-HD Post-HD Absolute HDHcy
Baseline 26.65.0 17.76.9 33.57.4% 25.35.9 16.94.9 — — 33.77.0%
(8.93.4 lmol/L) (8.42.1 lmol/L)
1 month 24.27.3 16.95.5 30.38.6% 21.54.5a 14.33.3a 15.05.1 15.419.7 32.94.9%
(7.32.8 lmol/L) (7.23.0 lmol/L)
3 months 23.98.8 15.88.1 33.910.6% 16.94.0b,d 12.13.8b 33.212.9 28.419.0 29.15.2%a,c
(8.13.3 lmol/L) (4.81.8 lmol/L)
6 months 25.97.3 16.36.6 37.113.6% 17.24.2b,d 12.46.1b,c 32.016.7 26.619.9 27.96.8%b,d
(9.63.9 lmol/L) (4.81.9 lmol/L)
Absolute HDHcy values were calculated as described in Methods. The mean level of tHcy in healthy controls was 10.52.6 mol/L.
aP  0.05 and bP  0.01 vs. baseline levels; cP  0.05 and dP  0.01 vs. control group values
in water and acetonitrile (90:10). The pH of this solution
was adjusted to 2.9 with concentrated phosphoric acid.
Hcy and other thiol compounds (cysteine, cysteinyl-
glycine, glutathione) were used to calibrate the method
throughout different steps of the sample preparation pro-
cedure and quantification of tHcy levels. Two different
solutions of the Hcy derivative prepared daily were used
as external standards and assessed in duplicate to make
appropriate standard curves.
The absolute decrease of tHcy during dialysis was cal-
culated using mean plasma levels of tHcy before (pre)
and after (post) HD according to the following equation:
HDHcy  ([Hcy]pre  [Hcy]post) 
 100/[Hcy]pre
In some experiments the amount of albumin that bound
Hcy in the spent dialysate proteins was measured. After
extensive dialysis against a solution of phosphate-buf-
fered saline (2 changes 
 5 hrs at 4	C using a 10 kD cut-
off nylon membrane), the albumin fraction was separated
by Cybacron Blue affinity chromatography (Affiland S.A.,
Ans-Lige, Belgium) and Hcy was analyzed (see above)
after reduction of the albumin-Hcy disulfide under dena-
turating conditions with an excess of mercaptoethanol.
A molar ratio of 1/1 was used to calculate the amount
of albumin to which Hcy is bound.
Protein assay
Plasma and dialysate proteins were measured with the
method of Bradford using the Bio-Rad Protein Assay kit
(Bio-Rad, Milan, Italy). The blue comassie chromogen
binds proteins to form a complex with a maximum ab-
sorbance at 595 nm. This versatile assay showed a good
linearity and reproducibility. However, depending on dif-
ferent sources of proteins and amino acid composition,
this method can lead to different results and preliminary
experiments showed that protein levels could be under-
estimated by approximately 15% when compared to other
procedures, such as the method of Lowry. This limit of
the assay did not affect the aims of the research, which
were to compare in a prospective evaluation the concen-
tration of total proteins in plasma and dialysate.
Statistics and data processing
The results are expressed as mean 1 standard devia-
tion (SD) or as median (range). The Student-Newman-
Keuls (SNK) test for multiple comparisons was applied
to evaluate differences among groups of patients. The
Student t test for paired data and the nonparametric
one-way analysis of variance (ANOVA) were used when
appropriate to compare data in the prospective study.
Regression analyses and data plotting were carried out
using the software MicrocalOrigin V.6 (Microcal Soft-
ware, Inc., Northampton, MA, USA). Probability values
of 0.05 were accepted, and values 0.01 were consid-
ered highly significant.
RESULTS
Effect of protein-leaking dialyzers on
hematochemical parameters
In the study group, hematochemical and dialysis pa-
rameters (Table 1) did not change significantly during
the treatment with protein-leaking dialyzers (not shown),
with the exception of hematocrit and total plasma pro-
tein and albumin levels. Hematocrit levels increased pro-
gressively from the baseline value of 32.5 4.1% to 37.1
3.8% at the end of the study (14.2%, P  0.01), and
total proteins and albumin decreased to the lower part
of the control range (6.0 to 8.4 g/dL and 3.5 to 5.0 g/dL,
respectively) during the first month of treatment with
protein-leaking dialyzers, but were restored as compared
to baseline evaluation in the remaining steps of the study.
In detail, total proteins (g/dL) were 6.9  0.5 at baseline
evaluation and 6.3  1.0 (8.7%), 6.7  0.7 (2.9%),
and 6.8  0.6 (1.4%) after 1, 3, and 6 months of treat-
ment with protein-leaking dialyzers. Albumin levels (g/
dL) were 4.0  0.4 and 3.7  0.6 (7.5%), 3.8  0.3
(5%) and 3.8  0.4 (5%).
Regarding the effect of protein-leaking dialyzers on
plasma levels of folic acid and vitamin B12, we did not
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Fig. 1. Individual and average pre-HD tHcy levels in patients on treat-
ment with protein-leaking dialyzer membranes (BK-F) over a period
of time of 6 months. The mean decrease of tHcy observed after 1, 3,
and 6 months of protein-leaking dialyzers is statistically significant with
respect to baseline evaluation (P  0.01).
find significant changes during the prospective study. In
the study group, folic acid levels (ng/mL) were 23.3 
19.5 at baseline and 20.8  20.2 after 6 months of treat-
ment with protein-leaking dialyzers; vitamin B12 (pg/mL)
levels were 379.3  169.5 at baseline and 370.6  203.7
after 6 months of treatment with protein-leaking dia-
lyzers.
In the control group, all these parameters were not
significantly modified at the different steps during the 6
months of the study (not shown).
Effect of protein-leaking dialyzers on tHcy levels
Baseline levels of tHcy in plasma were 26.6  5.0 and
25.3  5.9 mol/L, respectively, in the control and study
group (P  NS) (Table 3). These levels are significantly
higher compared with levels of tHcy measured in healthy
subjects (10.5 2.6 mol/L, P 0.001). After 6 months,
in the control group mean tHcy levels in pre-HD were
not significantly modified (27.4  5.9 mol/L), while in
the protein-leaking dialyzer group a significant decrease
was observed (17.2  4.2 mol/L, P  0.01 vs. control
group) (Fig. 1). Although this decrease kept mean levels
of tHcy significantly higher as compared to healthy con-
trols (P  0.01), 3 out of 12 patients in the protein-
leaking dialyzer group showed pre-HD levels of tHcy
below the arbitrary cut-off line represented from the
mean healthy control value 1 SD (13.1 mol/L). One
patient showed levels below the cut-off limit during the
entire time of the study on protein-leaking dialyzers.
In all the patients, tHcy concentration before HD was
positively correlated with tHcy assessed after HD (R 
0.642; P  0.001) and with plasma albumin levels (R 
0.323, P  0.020).
In both groups a significant difference between pre-
and post-HD tHcy levels was observed at every experi-
mental time (P  0.01). As shown in Table 3, pre- and
post-HD levels of tHcy steadily and progressively low-
ered in the study group in a similar way during the differ-
ent steps in the study, but remained the same in the
control group. The mean decrease of tHcy with respect to
baseline data improved during the steps of the treatment
with protein-leaking dialyzers both before and after HD,
with a mean value of decrease in pre-HD of approxi-
mately 15.0% at the first month and 32% after 3 and
6 months (P  0.01). In the control group the change
of pre- and post-HD tHcy during the different steps of
the study compared to baseline data was negligible in
each step.
In the control group, the baseline intra-HD decrease
of tHcy (HDHcy) was 33.5 7.4% and remained steadily
above the value of 30% during the study. No significant
differences were observed for the HDHcy of subgroups
of patients on different non-protein-leaking dialyzers (not
shown).
In the study group, the baseline HDHcy was 33.7 
7.0%, and after 1, 3, and 6 months, it decreased to
32.9  4.9% (P  NS), 29.1  5.2% (P  0.05), and
27.9  6.8% (P  0.01). A positive correlation between
HDHcy and pre-HD tHcy levels in all the patients at
different time-points was observed (R 0.666, P 0.02).
Hcy and protein content in spent dialysate samples
The total amount of proteins removed with standard
dialyzers was calculated to be 0.5 g/dialysis session
(median, 0.26, range, 0.20 to 0.32), while in the first
dialysis session with protein-leaking dialyzers it ranged
from 1.28 and 4.13 g (median, 2.86 g). In the spent dialy-
sate obtained from patients on protein-leaking dialyzers,
albumin was observed to be 75% to 90% (85%) of the
total protein, and the quota of albumin that bound Hcy
ranged from 33% to 86% (68%). From these data it can
be roughly calculated that the amount of bHcy removed
during a single dialysis session with protein-leaking dia-
lyzers and non-protein-leaking dialyzers is 25.0 and 2.3
mol, respectively.
DISCUSSION
Specific Hcy-lowering therapy and current dialysis pro-
cedures can provide only a limited correction of hyper-
homocysteinemia in a large portion of ESRD patients
[11, 15–17]. The main reason for this fruitless battle is
the sustained generation of Hcy by the impaired meta-
bolic and excretive functions and its accumulation in
the uremic blood mainly as bHcy (80%) [8]. The bHcy
form may represent a sort of reservoir in equilibrium
with the fHcy and tissue Hcy. The kinetics of exchange
between the free and bound forms and the continuous
refueling of Hcy from tissues could then keep the form
dialyzable with non-protein-leaking dialyzers (i.e., the
fHcy) too low compared to the bound one, which would
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limit the capability to affect the total pool of Hcy in the
body enormously.
In the last years, a new generation of dialyzers able
to remove proteins (protein-leaking dialyzers) has been
introduced in the HD practice. The first example in this
context was that of a PMMA-based membrane [18]. We
first characterized the performance of these dialyzers as
concerns protein leakage and removal of some classes
of high molecular weight solutes such as advanced gly-
coxidation end products and erythropoiesis inhibitors
[abstract; Galli F et al, J Am Soc Nephrol 12:1831, 2001]
[19, 21]. Recently, protein leakage by BK-F protein-
leaking dialyzers has been compared with that of other
high-flux membranes and protein-leaking dialyzers [24].
This comparison showed that the BK-F series provides
nearly five times greater protein leakage than PS-based
protein-leaking dialyzers (Superflux series from Fresen-
ius Medical Care Ag, Bad Homburg, Germany) and also
immunoglobulin G (IgG) could be detected in filtrate
samples.
In agreement with our early findings on PMMA-based
protein-leaking dialyzers [19], van Tellingen et al [22]
recently showed that PS-based protein-leaking dialyzers
could steadily reduce tHcy in blood of chronic HD pa-
tients. The underlying mechanism of this effect of pro-
tein-leaking dialyzers remains to be clarified and could
be of relevance in understanding the role of protein-
leaking dialyzers in the correction of other high-molecu-
lar-weight solutes. Hcy is only one of the several pro-
tein-bound toxins that, together with a number of still
unknown high-molecular-weight uremic solutes, could play
an important pathogenic role in different uremic comor-
bidities, such as uremic anemia, vascular damage, chronic
inflammation, and immune dysfunction [19, 21, 25, 26].
The present study first investigates in detail the effect
of PMMA-based protein-leaking dialyzers on tHcy levels
of folate-supplemented ESRD patients showing mild-
intermediate hyperhomocysteinemia. The results dem-
onstrate that pre-HD values of tHcy are steadily reduced
by PMMA-based protein-leaking dialyzers (BK-F). A
significant decrease was achieved already after 4 weeks
of treatment (15.0%), and reached a maximum at 3
months (33.2%). Importantly, after 6 months of protein-
leaking dialyzers, individual values of tHcy in 3 out of 12
patients fell below the arbitrary cut-off line represented
from the mean healthy control value  1 SD. This de-
crease of pre-HD tHcy in the study group largely exceeds
even the best results achieved here and in other studies
using high-flux membranes on patients showing mild
hyperhomocysteinemia [16]. This result was observed in
the presence of plasma folate levels and vitamin therapy
kept steady during the study. Since our patients showed
lower starting folate levels as compared with supple-
mented patients in other studies, a better effect of protein-
leaking dialyzers on tHcy correction in the presence of
Fig. 2. Components that may participate in lowering plasma tHcy dur-
ing dialysis with protein-leaking dialyzers and non-protein-leaking dia-
lyzers. The fHcy and bHcy fractions in plasma are in equilibrium with
them and with the tissue pool of fHcy. During pure diffusive dialysis
with conventional non-protein-leaking dialyzers, tHcy levels in plasma
can be reduced almost exclusively through the removal of fHcy (arrow
1). This leads to an intra-HD drop in tHcy (HDHcy) of approximately
30%, which is promptly restored in the first hours after HD by the
tissue reservoir. The same dialysis method carried out with protein-
leaking dialyzers can act on two other aspects that contribute to steadily
lower pre-HD tHcy. The first one is the removal of albumin-bound
Hcy or bHcy (arrow 2). In the present study this component of the
effect of protein-leaking dialyzers on plasma tHcy was shown to be
important but largely insufficient to explain the observed lowering of
tHcy in pre-HD. This aspect, in fact, does not explain why protein-
leaking dialyzers provide a similar HDHcy as non-protein-leaking dia-
lyzers, while removing 10 times greater amounts of bHcy. The second
aspect (arrow 3) could serve to explain this apparent paradox. As
previously suggested [22], protein-leaking dialyzers could remove some
still yet unidentified large molecular weight solutes able to impair meta-
bolic pathways responsible of the tissue recycling of Hcy. Abbreviations
are: b, bHcy; f, fHcy; ?, possible large molecular weight inhibitors of
Hcy metabolism
higher doses of this cofactor cannot be ruled out and
will be the subject of further investigation.
In the study group, a direct relationship was observed
between the intra-HD drop of tHcy (HDHcy) and pre-
HD tHcy. Accordingly, the HDHcy showed a slight but
progressive decrease during the treatment with protein-
leaking dialyzers. However, as shown in Table 3, at dif-
ferent time points in the protocol, protein-leaking dialyz-
ers used with a pure diffusive method maintain a good
efficacy to clear blood Hcy, but this is obviously a self-
limiting process regulated from pre-HD tHcy levels, with
a value of approximately 33% as the highest attainable
after 3 months of treatment.
These data on the reduction of tHcy levels in pre-HD
by BK-F protein-leaking dialyzers are in agreement with
the data obtained using PS-based protein-leaking dialyz-
ers [22]. However, that study did not investigate the
removal of proteins and Hcy with the dialysate and the
intra-HD reduction of tHcy, leading to the unsupported
hypothesis that protein-leaking dialyzers might reduce
tHcy by removing toxins that negatively influence the
metabolic processing of Hcy.
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In the present study, the analysis of spent dialysate
samples at the first dialysis with protein-leaking dialyzers
demonstrated that this membrane removes a total amount
of proteins per HD session more than 10 times the values
observed with non-protein-leaking dialyzers (median
values, 2.86 vs. 0.26 g/dialysis session). Moreover, it was
observed that in the dialysate, on average, 68% of the
molecules of albumin-bound Hcy with a molar ration of
1/1, and albumin is 85% of total plasma proteins in the
spent dialysate. These data led to rough estimates that
each dialysis session with protein-leaking dialyzers could
remove up to 25.0 mol of bHcy, while only 2.3 mol
are removed with non-protein-leaking dialyzers. In a
simplified monocompartment model in which the tHcy
would be distributed into 2.5 L of plasma, the bHcy
found in the spent dialysate corresponds to decreases of
tHcy of 10 and 0.9 mol/L, respectively, in the presence
of baseline levels of tHcy of approximately 25 mol/L.
Of course, these simplifications make the calculations to
overestimate the contribution that the removal of bHcy
might provide to lower plasma tHcy. In fact, the pool of
fHcy and its metabolic processing in the tissues, as well
as the changes of blood tHcy consequent to the treatment
with protein-leaking dialyzers treatment, can affect these
calculations. However, they give a hint of the relevance
of subtracting bHcy with BK-F protein-leaking dialyzers
in the context of the intra-HD drop of tHcy (HDHcy)
observed after 1 month (7.4 mol/L) and 3 months (4.4
mol/L) of treatment.
However, the finding that non-protein-leaking dialyz-
ers leads to a HDHcy similar to that of the protein-
leaking dialyzers at different time points in the study
(30% to 35% and 28% and 34%, respectively), but differ-
ent (more than 10 times greater) removal of bHcy, sug-
gests that the progressive and steady decline of pre-HD
tHcy is a consequence of the rapid restoration during
dialysis of the equilibrium of concentration between the
free and bound form of Hcy. This influences the tissue
output of Hcy and its clearance during HD, ultimately
representing a boundary in the correction of tHcy when
pure diffusive dialysis methods are used.
The data in this study seem to confirm the hypothesis
that protein-leaking dialyzers improve hyperhomocys-
teinemia mainly by removing large molecular weight sol-
utes able to affect the Hcy metabolism [22] and the
consequent refill of blood tHcy in the intra and inter-
HD intervals by the tissue pool, while the direct removal
of bHcy could play a less important role (Fig. 2). This
hypothesis is currently under further investigation in our
lab. Preliminary data confirm that at least a component
of this inhibitory activity of the uremic plasma shows a
proteinaceous nature while other factors may be low mo-
lecular weight solutes that can interfere with folate func-
tion and can be removed/inactivated during dialysis with
standard non protein-leaking dialyzers [Franceschini M,
Galli F, Floridi A, unpublished observation, 2003].
In regards to the widespread concern about the chronic
loss of grams of proteins (mainly albumin) in patients
already at risk for malnutrition and hypoalbuminemia
and its possible contribution to the incidence of cardio-
vascular morbidity and overall mortality [27], this study
demonstrated that the protein leakage achieved during
a standard dialysis with protein-leaking dialyzers (up to
4 g/dialysis session) is largely compensated in patients
who would show a good metabolic and nutritional status.
Moreover, preliminary data on patients on treatment for
more than 2 years with BK-F protein-leaking dialyzers
show good nutritional status and overall clinical condi-
tions (unpublished data).
CONCLUSION
In patients with mild to intermediate hyperhomocys-
teinemia supplemented with folates, the treatment with
protein-leaking dialyzers is effective in achieving a
steady, even if partial, correction in pre-HD levels of
tHcy (30% of decrease). The results leave further space
in the hypothesis that an accumulation of large molecular
weight inhibitors of the Hcy metabolism could be a major
underlying mechanism of hyperhomocysteinemia in HD
patients.
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